Cargando…

Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?

OBJECTIVES: Neoadjuvant immunochemotherapy (nICT) is a novel pattern for locally advanced esophageal squamous cell carcinoma (ESCC), and the time to surgery (TTS) is recommended as 4-6 weeks. However, there were some patients with prolonged TTS(> 6 weeks). This study aimed to explore whether prol...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Zhi-Nuan, Huang, Zhixin, Weng, Kai, Lin, Jihong, Kang, Mingqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614210/
https://www.ncbi.nlm.nih.gov/pubmed/36311738
http://dx.doi.org/10.3389/fimmu.2022.1036396
_version_ 1784820145699422208
author Hong, Zhi-Nuan
Huang, Zhixin
Weng, Kai
Lin, Jihong
Kang, Mingqiang
author_facet Hong, Zhi-Nuan
Huang, Zhixin
Weng, Kai
Lin, Jihong
Kang, Mingqiang
author_sort Hong, Zhi-Nuan
collection PubMed
description OBJECTIVES: Neoadjuvant immunochemotherapy (nICT) is a novel pattern for locally advanced esophageal squamous cell carcinoma (ESCC), and the time to surgery (TTS) is recommended as 4-6 weeks. However, there were some patients with prolonged TTS(> 6 weeks). This study aimed to explore whether prolonged TTS (> 6 weeks) would affect the outcomes. METHODS: Patients diagnosed with locally advanced ESCC between January 2020 and March 2022 and undergoing esophagectomy following nICT were identified based on a prospectively collected database. Primary outcome measures were pathological complete response (pCR) and disease-free survival (DFS), and the secondary outcomes were 30-day postoperative mortality and morbidity, surgical time, postoperative hospital stay, and hospital expense. RESULTS: Total of 95 patients were included for analysis, with 52 patients in the standard TTS group and 43 patients in the prolonged TTS group. The clinical and demographic characteristics of the two groups were comparable. The prolonged group had a median 18 days longer TTS(P<0.001). The pCR rate was 23.08% (12/52) in the standard group and 16.28% (7/43) in the prolonged group (P=0.41). Multivariate regression analysis further indicated that TTS wasn’t an independent factor in predicting pCR (P=0.41). The median follow-up time was 10.5 months in the standard TTS group and 11.2 months in the prolonged TTS group. A total of five recurrences occurred with two events in the standard TTS group and three events in the prolonged TTS group, and no significant difference was observed in DFS(P=0.60). Both groups were comparable in postoperative hospital stays, total hospital stay, hospital expenses, and comprehensive complications index (CCI). The complications and major complications were also similar in both groups. Spearman test further indicated that there was no linear correlation among TTS with hospital expenses, postoperative hospital stays, hospital stay, CCI index, lymph nodes moved number, or surgical time, with a p-value of 0.48, 0.63, 0.80, 0.92, 0.09, 0.38 respectively. CONCLUSIONS: Based on present evidence, TTS after completion of nICT is not of major importance concerning pathological response, disease-free survival, and short-term postoperative outcomes.
format Online
Article
Text
id pubmed-9614210
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96142102022-10-29 Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes? Hong, Zhi-Nuan Huang, Zhixin Weng, Kai Lin, Jihong Kang, Mingqiang Front Immunol Immunology OBJECTIVES: Neoadjuvant immunochemotherapy (nICT) is a novel pattern for locally advanced esophageal squamous cell carcinoma (ESCC), and the time to surgery (TTS) is recommended as 4-6 weeks. However, there were some patients with prolonged TTS(> 6 weeks). This study aimed to explore whether prolonged TTS (> 6 weeks) would affect the outcomes. METHODS: Patients diagnosed with locally advanced ESCC between January 2020 and March 2022 and undergoing esophagectomy following nICT were identified based on a prospectively collected database. Primary outcome measures were pathological complete response (pCR) and disease-free survival (DFS), and the secondary outcomes were 30-day postoperative mortality and morbidity, surgical time, postoperative hospital stay, and hospital expense. RESULTS: Total of 95 patients were included for analysis, with 52 patients in the standard TTS group and 43 patients in the prolonged TTS group. The clinical and demographic characteristics of the two groups were comparable. The prolonged group had a median 18 days longer TTS(P<0.001). The pCR rate was 23.08% (12/52) in the standard group and 16.28% (7/43) in the prolonged group (P=0.41). Multivariate regression analysis further indicated that TTS wasn’t an independent factor in predicting pCR (P=0.41). The median follow-up time was 10.5 months in the standard TTS group and 11.2 months in the prolonged TTS group. A total of five recurrences occurred with two events in the standard TTS group and three events in the prolonged TTS group, and no significant difference was observed in DFS(P=0.60). Both groups were comparable in postoperative hospital stays, total hospital stay, hospital expenses, and comprehensive complications index (CCI). The complications and major complications were also similar in both groups. Spearman test further indicated that there was no linear correlation among TTS with hospital expenses, postoperative hospital stays, hospital stay, CCI index, lymph nodes moved number, or surgical time, with a p-value of 0.48, 0.63, 0.80, 0.92, 0.09, 0.38 respectively. CONCLUSIONS: Based on present evidence, TTS after completion of nICT is not of major importance concerning pathological response, disease-free survival, and short-term postoperative outcomes. Frontiers Media S.A. 2022-10-14 /pmc/articles/PMC9614210/ /pubmed/36311738 http://dx.doi.org/10.3389/fimmu.2022.1036396 Text en Copyright © 2022 Hong, Huang, Weng, Lin and Kang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Hong, Zhi-Nuan
Huang, Zhixin
Weng, Kai
Lin, Jihong
Kang, Mingqiang
Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?
title Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?
title_full Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?
title_fullStr Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?
title_full_unstemmed Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?
title_short Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?
title_sort does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614210/
https://www.ncbi.nlm.nih.gov/pubmed/36311738
http://dx.doi.org/10.3389/fimmu.2022.1036396
work_keys_str_mv AT hongzhinuan doestimetoesophagectomyfollowingneoadjuvantimmunochemotherapyforlocallyadvancedesophagealsquamouscellcarcinomaaffectoutcomes
AT huangzhixin doestimetoesophagectomyfollowingneoadjuvantimmunochemotherapyforlocallyadvancedesophagealsquamouscellcarcinomaaffectoutcomes
AT wengkai doestimetoesophagectomyfollowingneoadjuvantimmunochemotherapyforlocallyadvancedesophagealsquamouscellcarcinomaaffectoutcomes
AT linjihong doestimetoesophagectomyfollowingneoadjuvantimmunochemotherapyforlocallyadvancedesophagealsquamouscellcarcinomaaffectoutcomes
AT kangmingqiang doestimetoesophagectomyfollowingneoadjuvantimmunochemotherapyforlocallyadvancedesophagealsquamouscellcarcinomaaffectoutcomes